Plain-English translation of NCT06688396 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a portable, smartphone-based heart scanner (called AliveCor KardiaMobile 6L) that uses artificial intelligence to detect early signs of a heart condition called dilated cardiomyopathy. If you have this condition, researchers are inviting your adult relatives to use this simple device at home or at a clinic to see if it encourages them to get proper heart screening. The goal is to find out if this easy-to-use technology helps catch heart problems early in families where the condition runs.
Dilated cardiomyopathy often runs in families, but many relatives of affected patients never get screened for the condition until it becomes serious. Researchers hope this mobile, artificial intelligence-enhanced heart scanner will make screening easier and more accessible, encouraging more family members to check their heart health early when treatment can help most.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will use the portable heart scanner (a small device that connects to a smartphone) to record a quick heart rhythm reading — the whole process takes just 30 seconds to 5 minutes. Your results will be analyzed by artificial intelligence software to check for signs of heart problems. Researchers will encourage you to follow up with a full cardiac screening from your doctor if recommended. The study team will compare your scanner results with traditional heart tests to see how accurate the new technology is.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States
Sponsor
Lancaster General Hospital
Collaborators
Mayo Clinic
Enrollment target
~150 participants
Started
December 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Halle Becker, MPH
Penn Medicine / Lancaster General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.